Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Strides Arcolab is currently trading at Rs. 694.95, up by 3.40 points or 0.49% from its previous closing of Rs. 691.55 on the BSE.
The scrip opened at Rs. 692.00 and has touched a high and low of Rs. 694.95 and Rs. 691.20 respectively.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 709.90 on 09-May-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 709.90 and Rs. 666.00 respectively. The current market cap of the company is Rs. 4,061.00 crore.
The promoters holding in the company stood at 28.35% while Institutions and Non-Institutions held 55.55% and 16.11% respectively.
Strides Arcolab (Strides) has received ANDA approval from USFDA for Acetazolamide Injection USP, 500 mg/ vial (preservative free) in lyophilized format. The product is expected to be launched shortly. According to IMS, the 2011 US market for Injectable Acetazolamide approximates to $10 million with only one active player.
Acetazolamide is the fourteenth product approved under the Sagent - Strides partnership. Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.
Acetazolamide is used for adjunctive treatment of - edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1517.90 |
| Dr. Reddys Lab | 6362.00 |
| Cipla | 1478.90 |
| Zydus Lifesciences | 1066.95 |
| Lupin | 1614.95 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
